Colon Targeting Drug Delivery Market to Witness Significant Growth of USD $2.03 Billion with 7.9% CAGR by 2029
Get 20% Off Market Intelligence Reports With Code ONLINE20 – Track Global Tariffs, Economic Shifts, and Sector Transformations
What Is the Growth Potential of the Colon Targeting Drug Delivery Market in the Next Decade?
The colon targeting drug delivery market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.5 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to the rising prevalence of colorectal diseases, increasing focus on localized drug delivery, the need for improved patient compliance, and the emergence of biologics and peptides.
The colon targeting drug delivery market size is expected to see strong growth in the next few years. It will grow to $2.03 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to the development of stimuli-responsive and nanotechnology-based delivery systems, growth in contract research and manufacturing services, regulatory agencies offering incentives and faster approval pathways, and targeted delivery of biologics and biosimilars. Major trends in the forecast period include advancement in pH-responsive, personalized medicine integration, use of AI and digital tools in formulation design, and increasing focus on oral colon delivery.
Claim your free report sample now:
What Are the Major Drivers Influencing the Colon Targeting Drug Delivery Market?
The rising prevalence of gastrointestinal diseases is expected to propel the growth of the colon targeting drug delivery market going forward. Gastrointestinal diseases refer to disorders affecting the digestive tract, including the stomach, intestines, and associated organs. The prevalence of gastrointestinal diseases is growing due to unhealthy dietary habits, which include excessive consumption of processed foods and low fiber intake that disrupt gut health and digestion. Colon targeting drug delivery is used in gastrointestinal diseases to ensure precise drug release at the site of inflammation or infection, enhancing therapeutic effectiveness and reducing systemic side effects. For instance, in June 2023, according to Crohn's and Colitis Canada, a nonprofit organization, the number of individuals affected by inflammatory bowel disease is projected to increase from 322,600 in 2023 (representing 0.8% of the population) to 470,000 by 2035 (1.1% of the population). Therefore, the rising prevalence of gastrointestinal diseases is driving the growth of the colon targeting drug delivery market.
Which Segment Holds the Largest Share in the Colon Targeting Drug Delivery Market?
The colon targeting drug delivery market covered in this report is segmented –
1) By Dosage Form: Tablets, Capsules, Microspheres, Nanoparticles, Other Dosage Form
2) By Technology: pH-Sensitive Systems, Time-Dependent Systems, Microbially Triggered Systems, Pressure-Controlled Systems, Other Technologies
3) By Application: Inflammatory Bowel Disease, Colorectal Cancer, Infectious Diseases, Other Application
4) By End-User: Hospitals, Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Tablets: Extended-Release Tablets, Enteric-Coated Tablets, Osmotic Pump Tablets
2) By Capsules: Hard Gelatin Capsules, Soft Gelatin Capsules, Enteric-Coated Capsules
3) By Microspheres: Polymeric Microspheres, Biodegradable Microspheres, Non-biodegradable Microspheres
4) By Nanoparticles: Polymeric Nanoparticles, Solid Lipid Nanoparticles, Dendrimers, Lipid-Polymer Hybrid Nanoparticles
4) By Other Dosage Form: Films, Injections, Hydrogels, Suppositories
Which Trends Are Positively Affecting the Colon Targeting Drug Delivery Market Expansion?
Major companies operating in the colon targeting drug delivery market are focusing on developing innovative drug delivery solutions, such as functional oral dosage forms, to improve targeted drug release, enhance therapeutic efficacy, and minimize side effects. Functional oral dosage forms are used in colon targeting drug delivery to protect active pharmaceutical ingredients from degradation in the upper gastrointestinal tract and ensure their controlled release specifically in the colon. For instance, in September 2024, Evonik Industries AG, a Germany-based specialty chemicals company, launched EUDRACAP Functional, a ready-to-fill capsule technology for the targeted delivery of oral drugs to the colon. This advanced solution enables precise release by using pH-sensitive polymers that dissolve only at specific intestinal pH levels, ensuring the API reaches the colon intact. By enabling oral delivery of complex APIs such as peptides and probiotics, EUDRACAP Functional supports the development of patient-friendly therapies and expands the possibilities for treating chronic gastrointestinal disorders with greater accuracy and reduced systemic exposure.
Which Major Companies Are Operating in the Colon Targeting Drug Delivery Market?
Major companies operating in the colon targeting drug delivery market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Evonik Industries AG, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Lonza Pharma AG, Ferring Pharmaceuticals Company Limited, Salix Pharmaceuticals Ltd., Tillotts Pharma AG, BDD Pharma Ltd., Tharimmune Inc.
Get the full colon targeting drug delivery market report here:
Which Region Is Expected to Lead the Colon Targeting Drug Delivery Market by 2029?
North America was the largest region in the colon targeting drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the colon targeting drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment